Literature DB >> 17084552

Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia.

Ed R Blazek1, Jennifer L Foutch, Guitta Maki.   

Abstract

PURPOSE: Primary medulloblastoma and glioblastoma multiforme tumor cells that express the surface marker CD133 are believed to be enriched for brain tumor stem cells because of their unique ability to initiate or reconstitute tumors in immunodeficient mice. This study sought to characterize the radiobiological properties and marker expression changes of CD133+ vs. CD133- cells of an established medulloblastoma cell line. METHODS AND MATERIALS: Daoy and D283 Med cell lines were stained with fluorescently labeled anti-CD133 antibody and sorted into CD133+ and CD133- populations. The effect of oxygen (2% vs. 20%) on CD133 expression was measured. Both populations were analyzed for marker stability, cell cycle distribution, and radiosensitivity.
RESULTS: CD133+ Daoy cells restored nearly native CD133+ and CD133- populations within 18 days, whereas CD133- cells remained overwhelmingly CD133-. Culturing Daoy cells in 2% oxygen rather than the standard 20% oxygen increased their CD133 expression 1.6-fold. CD133+ Daoy cells were radioresistant via the beta-parameter of the linear-quadratic model relative to CD133- Daoy cells, although their alpha-parameters and cell cycle distributions were identical.
CONCLUSIONS: Restoration of the original CD133+ and CD133- populations from CD133+ Daoy cells in serum is further evidence that CD133+ cells are functionally distinct from CD133- cells. The radioresistance of CD133+ compared with CD133- Daoy cells is consistent with better repair of sublethal damage. Enlargement of the CD133+ sector is a new feature of the hypoxic response.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17084552     DOI: 10.1016/j.ijrobp.2006.09.037

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  90 in total

1.  CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope.

Authors:  Anthony B Mak; Kim M Blakely; Rashida A Williams; Pier-Andrée Penttilä; Andrey I Shukalyuk; Khan T Osman; Dahlia Kasimer; Troy Ketela; Jason Moffat
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  Characterisation of normal and cancer stem cells: one experimental paradigm for two kinds of stem cells.

Authors:  Jean-François Mayol; Corinne Loeuillet; Francis Hérodin; Didier Wion
Journal:  Bioessays       Date:  2009-09       Impact factor: 4.345

3.  CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116.

Authors:  Claudia Dittfeld; Antje Dietrich; Susann Peickert; Sandra Hering; Michael Baumann; Marian Grade; Thomas Ried; Leoni A Kunz-Schughart
Journal:  Radiother Oncol       Date:  2010-03       Impact factor: 6.280

4.  Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.

Authors:  Gregory K Friedman; Blake P Moore; Li Nan; Virginia M Kelly; Tina Etminan; Catherine P Langford; Hui Xu; Xiaosi Han; James M Markert; Elizabeth A Beierle; G Yancey Gillespie
Journal:  Neuro Oncol       Date:  2015-07-16       Impact factor: 12.300

5.  The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype.

Authors:  John M Heddleston; Zhizhong Li; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell Cycle       Date:  2009-10-03       Impact factor: 4.534

6.  HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression.

Authors:  Jacqueline Kessler; Antje Hahnel; Henri Wichmann; Swetlana Rot; Matthias Kappler; Matthias Bache; Dirk Vordermark
Journal:  BMC Cancer       Date:  2010-11-04       Impact factor: 4.430

7.  Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis.

Authors:  Ryan Morrison; Stephen M Schleicher; Yunguang Sun; Kenneth J Niermann; Sungjune Kim; Daniel E Spratt; Christine H Chung; Bo Lu
Journal:  J Oncol       Date:  2010-10-12       Impact factor: 4.375

Review 8.  Glioma stem cell research for the development of immunotherapy.

Authors:  Jianfei Ji; Keith L Black; John S Yu
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

9.  MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma.

Authors:  Livia Garzia; Immacolata Andolfo; Emilio Cusanelli; Natascia Marino; Giuseppe Petrosino; Daniela De Martino; Veronica Esposito; Aldo Galeone; Luigi Navas; Silvia Esposito; Sara Gargiulo; Sarah Fattet; Vittoria Donofrio; Giuseppe Cinalli; Arturo Brunetti; Luigi Del Vecchio; Paul A Northcott; Olivier Delattre; Michael D Taylor; Achille Iolascon; Massimo Zollo
Journal:  PLoS One       Date:  2009-03-24       Impact factor: 3.240

Review 10.  Stemming cancer: functional genomics of cancer stem cells in solid tumors.

Authors:  C R A Regenbrecht; H Lehrach; J Adjaye
Journal:  Stem Cell Rev       Date:  2008-12       Impact factor: 5.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.